Abstract
Previous studies have shown that diaspirin cross-linked hemoglobin (DCLHb(TM), 10 g/dL) decreases cerebral ischemia and the resultant injury in a dose-dependent manner, requiring large volumes of DCLHb(TM) for maximum efficacy. We assessed the effect of a more concentrated (20 g/dL) and more hyperoncotic preparation of DCLHb(TM) on cerebral infarction volume. immediately after middle cerebral artery occlusion, rats were randomized to one of the following groups: Control, hematocrit not manipulated; 10/Hb, hematocrit decreased to 30% with 10% DCLHb(TM) (oncotic pressure 43 mm Hg); 7.5/Alb, hematocrit decreased to 30% with 7.5% albumin (oncotic pressure 43 mm Hg); 20/Hb, the same dose of DCLHb(TM) (20%, oncotic pressure 129 mm Hg) as the 10/Hb group (half the volume); or 15/Alb, the same dose of albumin (15%, oncotic pressure 130 mm Hg) as the 7.5/Alb group (half the volume). After 90 min of ischemia, 72 h of reperfusion was allowed. Infarction volume (mm3, mean ± SD) was less in the DCLHb(TM) groups (10/Hb = 79 ± 17; 20/Hb = 51 ± 14) than the oncotically matched albumin groups (7.5/Alb = 124 ± 21; 15/Alb = 85 ± 18) and the Control group (135 ± 17) (P < 0.05). These data indicate that in this model of cerebral ischemia, DCLHb(TM) decreases ischemic brain injury more effectively than albumin, and that a hyperoncotic preparation of DCLHb(TM) is preferable.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 342-347 |
| Number of pages | 6 |
| Journal | Anesthesia and Analgesia |
| Volume | 83 |
| Issue number | 2 |
| DOIs | |
| State | Published - 1996 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Anesthesiology and Pain Medicine
Cite this
Effect of oncotic pressure of diaspirin cross-linked hemoglobin (DCLHb(TM)) on brain injury after temporary focal cerebral ischemia in rats. / Cole, Daniel J.; Drummond, John C.; Patel, Piyush M.; Nary, Jeffrey C.; Applegate, Richard Lee.
In: Anesthesia and Analgesia, Vol. 83, No. 2, 1996, p. 342-347.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effect of oncotic pressure of diaspirin cross-linked hemoglobin (DCLHb(TM)) on brain injury after temporary focal cerebral ischemia in rats
AU - Cole, Daniel J.
AU - Drummond, John C.
AU - Patel, Piyush M.
AU - Nary, Jeffrey C.
AU - Applegate, Richard Lee
PY - 1996
Y1 - 1996
N2 - Previous studies have shown that diaspirin cross-linked hemoglobin (DCLHb(TM), 10 g/dL) decreases cerebral ischemia and the resultant injury in a dose-dependent manner, requiring large volumes of DCLHb(TM) for maximum efficacy. We assessed the effect of a more concentrated (20 g/dL) and more hyperoncotic preparation of DCLHb(TM) on cerebral infarction volume. immediately after middle cerebral artery occlusion, rats were randomized to one of the following groups: Control, hematocrit not manipulated; 10/Hb, hematocrit decreased to 30% with 10% DCLHb(TM) (oncotic pressure 43 mm Hg); 7.5/Alb, hematocrit decreased to 30% with 7.5% albumin (oncotic pressure 43 mm Hg); 20/Hb, the same dose of DCLHb(TM) (20%, oncotic pressure 129 mm Hg) as the 10/Hb group (half the volume); or 15/Alb, the same dose of albumin (15%, oncotic pressure 130 mm Hg) as the 7.5/Alb group (half the volume). After 90 min of ischemia, 72 h of reperfusion was allowed. Infarction volume (mm3, mean ± SD) was less in the DCLHb(TM) groups (10/Hb = 79 ± 17; 20/Hb = 51 ± 14) than the oncotically matched albumin groups (7.5/Alb = 124 ± 21; 15/Alb = 85 ± 18) and the Control group (135 ± 17) (P < 0.05). These data indicate that in this model of cerebral ischemia, DCLHb(TM) decreases ischemic brain injury more effectively than albumin, and that a hyperoncotic preparation of DCLHb(TM) is preferable.
AB - Previous studies have shown that diaspirin cross-linked hemoglobin (DCLHb(TM), 10 g/dL) decreases cerebral ischemia and the resultant injury in a dose-dependent manner, requiring large volumes of DCLHb(TM) for maximum efficacy. We assessed the effect of a more concentrated (20 g/dL) and more hyperoncotic preparation of DCLHb(TM) on cerebral infarction volume. immediately after middle cerebral artery occlusion, rats were randomized to one of the following groups: Control, hematocrit not manipulated; 10/Hb, hematocrit decreased to 30% with 10% DCLHb(TM) (oncotic pressure 43 mm Hg); 7.5/Alb, hematocrit decreased to 30% with 7.5% albumin (oncotic pressure 43 mm Hg); 20/Hb, the same dose of DCLHb(TM) (20%, oncotic pressure 129 mm Hg) as the 10/Hb group (half the volume); or 15/Alb, the same dose of albumin (15%, oncotic pressure 130 mm Hg) as the 7.5/Alb group (half the volume). After 90 min of ischemia, 72 h of reperfusion was allowed. Infarction volume (mm3, mean ± SD) was less in the DCLHb(TM) groups (10/Hb = 79 ± 17; 20/Hb = 51 ± 14) than the oncotically matched albumin groups (7.5/Alb = 124 ± 21; 15/Alb = 85 ± 18) and the Control group (135 ± 17) (P < 0.05). These data indicate that in this model of cerebral ischemia, DCLHb(TM) decreases ischemic brain injury more effectively than albumin, and that a hyperoncotic preparation of DCLHb(TM) is preferable.
UR - http://www.scopus.com/inward/record.url?scp=0030036991&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030036991&partnerID=8YFLogxK
U2 - 10.1097/00000539-199608000-00024
DO - 10.1097/00000539-199608000-00024
M3 - Article
C2 - 8694316
AN - SCOPUS:0030036991
VL - 83
SP - 342
EP - 347
JO - Anesthesia and Analgesia
JF - Anesthesia and Analgesia
SN - 0003-2999
IS - 2
ER -